MedTech West professor Paul Hockings´ new position at Antaros

Paul Hockings, Adjunct Professor at MedTech West since 2013, has recently joined Antaros Medical AB based at the BioVenture Hub in Mölndal, Sweden, as Director of Imaging. Antaros is a unique service provider of innovative MRI/PET imaging techniques to small biotech as well as big pharma. Antaros focuses on small to medium sized studies (10-300 patients) enabling solid decision making after phase 1b and phase 2; as well as providing strong foundation for differentiation of products in the life cycle management space. Core competencies –scientifically, technically and drug development wise- are in the cardiometabolic space. In his new role Paul will partner with potential clients to identify imaging endpoints that enable drug development in the safest, fastest, most cost effective way possible. He will be pivotal in the planning, design and execution of subsequent imaging clinical trials. Paul is an expert in the use of medical imaging technologies for the pharmaceutical industry. During his 20+ years of experience at SmithKline Beecham Pharmaceuticals, GlaxoSmithKline and AstraZeneca Paul has developed novel imaging biomarkers to quantitate disease progression and regression. He has established and led imaging groups in the UK and Sweden to deliver solutions to complex biomedical questions.

– My link to MedTech West is even more important in this new role, says Paul Hockings. MedTech West is a platform that will allow innovative new imaging endpoints to be road tested for ease of use and robustness before being applied in clinical trials. The qualification of new imaging biomarkers is a well-known bottleneck for drug development.